Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
Date:3/25/2009

,156) (650) 232% (7,371) (2,333) 216% General and administrative expenses (14,321) (5,915) 142% (49,400) (30,330) 63% Impairment charges (60,497) -- * (60,497) -- * Total operating expenses (76,974) (6,565) * (117,268) (32,663) 259% Operating income (loss) (56,700) 9,347 * (20,926) 30,195 * Other income (expenses), net: Other income (expenses), net 1,586 1,593 (0%) 1,046 2,435 (57%) Interest income (expenses), net 270 2,182 (88%) 913 2,771 (67%) Total other income (expenses), net 1,856 3,775 (51%) 1,959 5,206 (62%) Income (loss) from continuing operations before income taxes (54,844) 13,122 * (18,967) 35,401 * Income tax expenses (benefits) 5,605 (991) * 4,016 (1,498) * Income (loss) from continuing operations (49,239) 12,131 * (14,951) 33,903 * Loss on discontinued operations, net (Note 1) Loss from operations of discontinued component (54,290) -- * (61,665) -- * Income tax benefit 9,678 -- * 12,413 -- * Loss on discontinued operations (44,612) -- * (49,252) -- * Net income (loss) (93,851) 12,131 * (64,203) 33,903 * Basic net earnings (loss) per ADS: Earnings (loss) from continuing operations (0.74) 0.20 * (0.23) 0.56 * Loss on discontinued operations-net of tax (Note 1) (0.68) -- * (0.78) -- * Net earnings (loss) per ADS (1.42) 0.20 * (1.01) 0.56 * Weighted average AD
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related biology technology :

1. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
2. Quest PharmaTech Announces Strategic Alliance with IntelligentNano to Develop Nanotechnology-Based Next Generation SL052
3. Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
4. Quest PharmaTech Announces a Review of Strategic Alternatives to Enhance Shareholder Value
5. WuXi PharmaTech to Present at 27th Annual J.P. Morgan Healthcare Conference
6. Pharmatech 2.0: Introducing Pharmatech Oncology
7. WuXi PharmaTech Will Focus U.S. Operations on Laboratory Testing Services
8. WuXi PharmaTech Appoints Ying Han to Its Board of Directors
9. WuXi PharmaTech Announces Third Quarter 2008 Results
10. WuXi PharmaTech Signs New Collaboration Agreement With Pfizer
11. WuXi PharmaTech Schedules Third Quarter 2008 Earnings Release on Wednesday, November 12, 2008

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...rbleEnergyCorp.announcedtodaythatthecompanyandtheO...warded$2millionbyWashingtonState,sCommunityEconomi...shiptoconstructthestate,sfirstspecialtybiochemical...ntwillsignificantlyspeedthedevelopmentofourbiorefi...ueMarbleEnergyCEOKellyOgilvie."WearegratefultotheG...
(Date:11/24/2009)...Call/--Shireplc(LSE:SHP,NASDAQ: SHPGY ),theglobal...hatithassubmittedaMAAtotheEuropeanMedicinesAgencyf...therapyindevelopment,forthetreatmentofType1Gaucher...glucerasealfathathasbeensubmitted,withprevious,sub...aglobalsupplyshortageofthecurrentlyapprovedandmark...
(Date:11/24/2009)... Customers with Partners Validated to Process and ...s , Ottawa, ON (PRWEB) No...er of products for biological sample collection, s...new global partner program. The program offers sig...mmunity and is designed to help partners scale and...
(Date:11/23/2009)...origami very high-tech origami. , Researchers at...ique for fabricating three-dimensional, single-cry...pling photolithography and a self-folding process ...ly a few microns thick, offer mechanical bendabili... same material. , "This is a completely different...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3Water droplets direct self-assembly process in thin-film materials 2
...(OTC: NNLX) -- NanoLogix Inc. has begun constructi...t its headquarters in Hubbard, Ohio. It will cont...d shipping and receiving area to be used in the fa...he revolutionary new BNP(TM) kits provide accelera...600% faster than conventional Petri plate testing....
...al General Meeting of Syngenta AG on 21 April 2009...ed by the Board of Directors. , , Shareholders a...usiness year 2008, an increase of 25% over the pre... of the share capital to CHF 9,459,984.90 through ...mpany repurchased in 2008 within the scope of the ...
...c. (Nasdaq: ITMN ) announced today that it will ...ursday, April 30, 2009 at 4:00 p.m. Eastern time. ... by InterMune at 4:30 p.m. Eastern time that same ... 888-799-0528 (U.S.) or 973-200-3372 (internationa...t, please log on to the company,s website at www....
Other Biology Technology:NanoLogix Begins Construction of Production Facility for Medical Test Kits 2NanoLogix Begins Construction of Production Facility for Medical Test Kits 3Syngenta holds Annual General Meeting 2InterMune to Release First Quarter Financial Results on April 30 2
(Date:11/24/2009)...thousands of years it has been prescribed by tradi...nts from headaches and stomach pain to fever and f...astle University have been able to scientifically ...nata otherwise known as Brazilian mint. , Testi...eam led by researcher Graciela Rocha was able to s...
(Date:11/24/2009)...et science is opening new doors to understanding h...the hearing of a marine mammal or if they hear it...ed X-ray scanners that NASA uses to detect flaws i...is now allowing scientists to peek inside the gian...d three-dimensional replicas of a whale,s hearing ...
(Date:11/24/2009)...ts that keep weakened and flabby arteries from col...months, those stents are no longer needed -- once ...sary. Previously, doctors had no choice but to lea...l Aviv University,s Department of Biomedical Engin...atform that carries drugs where they,re needed, th...
Breaking Biology News(10 mins):Got a pain? -- Have a cup of Brazilian mint 2Rocket science leads to new whale discovery 2A coating for life 2Number of Californians with No Health Insurance is Rising says MedicareSupplementPlans com 53694 1Number of Californians with No Health Insurance is Rising says MedicareSupplementPlans com 53694 2Andrew Allen joins Navvis 26amp 3B Company 53689 1Andrew Allen joins Navvis 26amp 3B Company 53689 2Misonix Announces the Sale of Its Labcaire Business for up to 245 6 Million 53684 1Misonix Announces the Sale of Its Labcaire Business for up to 245 6 Million 53684 2Misonix Announces the Sale of Its Labcaire Business for up to 245 6 Million 53684 3
...e floor may not always show it, but people are rar...struct our arms and legs to grow in the right plac...ovide for the spaces between our fingers and toes ...Evolutionarily speaking, the genetic instructions ...g perfected more than half a billion years ago in ...
...hat only one strain of an infectious disease can e...se. In a study in the August issue of The American...y of Warwick) use a mathematical model to help exp... interact is all-important. The researchers found ...e strains result from monogamous populations. , "...
...scopically into the closest freshwater pond, you,d...er, you,d probably notice an oddly furry, pear-sha...hing in its path. , This tiny predator has a big...ub among scientists, as a star organism for resear...quenced, assembled, and analyzed T. thermophila ,...
Other Biology News:UF scientists discover evolutionary origin of fins, limbs 2UF scientists discover evolutionary origin of fins, limbs 3What's shaped like a pear and has 2 genomes? Check the pond 2What's shaped like a pear and has 2 genomes? Check the pond 3
Mouse Anti-IgG2 (Fc, gamma-2 epitope) Monoclonal Antibody, Unconjugated, Clone 52G1 from Meridian Life Science, Inc.
Corning Culture Flask, 150 cm2, Tc-Treated, Angled Neck, Vent Cap, Sterile from Sigma-Aldrich
Gel Loading Buff 6x from ABgene
Gel Loading Solution (Type I) from Sigma-Aldrich
Biology Products: